NEW YORK (GenomeWeb) – BG Medicine, which said last month it had laid off more than half of its staff, said in a regulatory document on Friday that it has suspended further payments to its non-employee board directors, effective Oct. 1.

The company said in a document filed with the US Securities and Exchange Commission that it has stopped cash payments and equity compensation to its non-employee directors in order to use its resources for "other operational purposes." It added that it will re-evaluate its policy for paying non-employee directors in 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.